JAK Inhibitors Have Good Outcomes in Difficult-to-Treat Rheumatoid Arthritis Patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Arthritis Res. Ther. 2022 Mar 01;24(1)61, S Ochi, K Sonomoto, S Nakayamada, Y TanakaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.